Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Metagenomi, Inc.

Get SEC filing alerts via email and in your feed for Metagenomi, Inc.

MGX

Metagenomi, Inc.

About Metagenomi, Inc.

Metagenomi, Inc. is a genetic medicines company specializing in genome editing technologies. Using proprietary metagenomics, AI, and advanced molecular tools, it develops precise, durable gene editing systems for treating genetic and protein deficiency diseases. Its portfolio includes in vivo therapies for hemophilia A, secreted protein disorders, and collaborations targeting cardiometabolic conditions, aiming to deliver potentially curative, one-time treatments across multiple organs and disease areas.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Metagenomi, Inc.

1
1
Metagenomi, Inc. Metagenomi Reports $23.1 Million Net Loss in Q1 2026, Revenue Declines

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Metagenomi, Inc. Metagenomi Therapeutics Reports Financial Results and Operational Progress in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Metagenomi, Inc. Metagenomi Reports Decrease in Collaboration Revenue and Increased Net Loss for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Metagenomi, Inc. Metagenomi Reports Significant Revenue Decline and Increased Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Metagenomi, Inc. Metagenomi Reports Q1 2025 Financial Results, Collaboration Revenue Drops to $4.1 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Metagenomi, Inc. Metagenomi Reports $78.1 Million Net Loss for 2024, Highlights IPO and R&D Progress

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Metagenomi, Inc. Metagenomi Reports Q3 2024 Financial Results, Net Loss of $18.8M, and Anticipates Continued Investment in Research and Development

Via official filing (AI summary) | over 1 year ago | 0 comments